

ORYZON to Present at *The Epigenetics Discovery Congress* in LONDON

BARCELONA/ CAMBRIDGE, MA, August 31th 2015 – Oryzon, a clinical stage epigenetic biopharmaceutical company, today announced that it will be presenting at The Epigenetics Discovery Congress to be held at the London Heathrow Marriot Hotel in LONDON on September 24-25.

The company will be represented by its CSO, Dr. Tamara Maes, who will review the last data of the company programs within the Session entitled: *LSD1 inhibitors for treatment of oncological and neurodegenerative disease* that will be held from 17.15 to 17.45 on September 24th.

Oryzon's first clinical asset, a LSD1 inhibitor for the treatment of leukemia and other malignancies, currently in Phase I/IIA was partnered in a global deal with ROCHE. Under the terms of the agreement, Oryzon received an upfront payment and near-term milestones totaling \$21 million, plus potential development, commercial and sales milestone payments across haematology, cancer and non-malignant indications that could exceed \$500 million, together with tiered royalties on sales which range up to mid-double digits. The company is now completing the preclinical development of ORY-2001, a drug that has demonstrated that stops cognitive impairment in Alzheimer's animal model and has a very good safety profile. The molecule is expected to get IND/CTA by year's end.

ABOUT ORYZON

Founded in 2000 in Barcelona, Spain, Oryzon (www.oryzon.com) is a privately held, clinical stage biopharmaceutical company considered as the European champion in Epigenetics with one of the strongest portfolio in the field. Its LSD1 program is currently covered by 19 patent families and has rendered one compound in clinical trials and another one to enter clinical trials by the beginning of 2016. In addition, Oryzon has ongoing programs for developing inhibitors against other histone demethylases and histone methyltransferases. The company has also a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. In October 2014, ORYZON announced opening of U.S. operations in Cambridge, Massachusetts through its U.S. affiliate, Oryzon Corp.

For more information

ATREVIA**Ana Melgar**amelgar@atrevia.com

Tlf. 915640725

Emili Torrell

Business Development Officer

etorrell@oryzon.com